Jim Dimetrios Colomvakos

Title: Jim Dimetrios Colomvakos: Innovator in Pharmaceutical Development

Introduction

Jim Dimetrios Colomvakos is a notable inventor based in Scarborough, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target critical biological processes. With a total of two patents to his name, Colomvakos is recognized for his innovative approaches to treating various diseases.

Latest Patents

Colomvakos's latest patents focus on crystalline forms of a CD73 inhibitor. These crystalline forms of the compound of Formula (I) modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto. The patents describe compositions containing the compound and methods for preparing these crystalline forms. Furthermore, the use of such crystalline forms and compositions is aimed at the treatment and prevention of a diverse array of diseases, disorders, and conditions, including cancer and immune-related disorders that are mediated by 5′-nucleotidase, ecto.

Career Highlights

Colomvakos is currently associated with Arcus Biosciences, Inc., where he continues to advance his research and development efforts. His work is pivotal in the pharmaceutical industry, contributing to innovative solutions for complex health issues.

Collaborations

Some of his notable coworkers include Andrew M K Pennell and Eric F Connor. Their collaborative efforts enhance the research environment and foster innovation within their projects.

Conclusion

Jim Dimetrios Colomvakos exemplifies the spirit of innovation in the pharmaceutical field. His contributions through patents and collaborative work are paving the way for advancements in medical treatments.